Hypocomplementemic urticarial vasculitis syndrome: a look beyond urticarial lesions

Helena Pires Pereira, Marta Pires Alves, Iolanda Alen Coutinho, Isabel Carrapatoso, Ana Todo-Bom

Allergy and Clinical Immunology Department, Coimbra University Hospital Center, Coimbra, Portugal

Adv Dermatol Allergol 2023; XL (4): 571–573 DOI: https://doi.org/10.5114/ada.2023.130474

Hypocomplementemic urticarial vasculitis syndrome (HUVS) is a rare leukocytoclastic vasculitis characterized by recurrent urticarial lesions and hypocomplementemia, often associated with other systemic symptoms such as fever, arthralgias, arthritis, abdominal pain as well as ocular, renal, pulmonary and gastrointestinal involvement. It is the most severe form of three distinct urticarial vasculitis: normocomplementemic urticarial vasculitis, hypocomplementemic urticarial vasculitis (limited to the skin or secondary to a systemic inflammatory disease) and hypocomplementemic urticarial vasculitis syndrome (McDuffie syndrome). The latter is considered by some to be a condition independent of other systemic inflammatory diseases as most cases are idiopathic, yet the syndrome may occur in association with autoimmune diseases, drug reactions, infections or malignancy [1, 2]. Skin findings of this disease can be difficult to distinguish from those of other types of urticaria, namely chronic spontaneous urticaria (CSU).

A 70-year-old female presented at the emergency department with sudden onset abdominal pain and distension, fever, anorexia and diarrhoea. She mentioned recurring generalized arthralgias with 4-week evolution as well as recurrent, intensely pruritic urticaria-like lesions lasting more than 24 h, primarily localized in the abdomen and lower extremities, without angioedema, that did not improve with antihistamine therapy, within the previous 6 months (Figures 1 A, B).

The patient had a previous history of well-controlled CSU, diagnosed over 30 years ago, without any skin lesions nor need for medication. Recently she was being closely followed by an Haematology specialist for suspected chronic lymphocytic leukemia.

In laboratory analysis, anemia, elevated erythrocyte sedimentation rate, eosinophilia, decreased complement fragments (C3, C4 and CH50), and impaired kidney function with proteinuria and haematuria were detected (Table 1). Immunological analysis of serum was highly positive for anti-C1q autoantibodies at 67.9 U/ml (normal range: < 10 U/ml) and negative for p-ANCA (perinuclear anti-neutrophil cytoplasmic antibodies), c-ANCA (cytoplasmic ANCA), ANA (antinuclear antibodies) and cryoglobulins. Viral serologies such as hepatitis, Epstein Barr and SARS-CoV2 were all found to be negative.

Imagiological findings revealed generalized lymphadenopathy, hepatosplenomegaly and polyserositis (ascites, pleural and pericardial effusion) (Figure 1 C).

Although skin lesions were initially attributed to CSU, after being evaluated by an allergy specialist, a decision to perform skin biopsy was made, due to some of the atypical characteristics of the skin lesions. Biopsy showed damage of dermal vessels with an infiltrate in the superficial and deep dermis (either perivascular or interstitial dermis), consisting of neutrophils and numerous eosinophils. Distortion of the architecture of multiple capillary vessels and deposition of eosinophilic and basal debris were observed. Eosinophils and basophils on collagen fibres, outlining formation of candle flame figures were also observed suggesting urticarial vasculitis. Therefore, a diagnosis of hypocomplementemic vasculitis syndrome was made in the setting of a paraneoplastic manifestation of the haematological malignancy.

The patient was started on corticosteroid therapy (prednisolone 0.5 mg/kg/day) with progressive clinical improvement of the dermatological findings (asymptomatic residual hyperpigmentation of the skin), absence of fever and other systemic symptoms, as well as laboratory improvement. Treatment was stopped after 4 weeks of therapy with complete regression of the skin lesions and normalized complement levels, haemoglobin and eosinophil count and normal renal function (Table 1).

HUVS is a rare condition with a wide variety of associated manifestations, therefore its pathophysiology is not yet completely understood, although it is considered to be mediated by antigen-antibody complexes that are deposited on vascular lumina, resulting in complement activation through the classical pathway [1, 2]. The association between HUVS and malignancies, particularly

Address for correspondence: Helena Pires Pereira MD, Coimbra University Hospital Center, Praceta Professor Mota Pinto, 3000-561, Coimbra, Portugal, phone: +351239400400, e-mail: helenapereira089@gmail.com Received: 7.01.2023, accepted: 7.02.2023.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/)

Parameter	Laboratory results		Reference values
	Initial	4 weeks of treatment	
Haemoglobin [g/dl]	10.0	11.3	11.8–15.8
Eosinophil [× 10 ⁶ /l]	1730	100	20–500
Anti-C1q [U/ml]	67.9	-	< 10
C1q [g/l]	0.089	0.204	0.100–0.250
C3 [g/l]	0.73	0.85	0.83–1.93
C4 [g/l]	0.08	0.22	0.15–0.57
CH50 [U/ml]	39.1	47.0	41.7–95.1
Erythrocyte sedimentation rate [mm/h]	39.0	18.0	1–20
Creatinine [mg/dl]	2.19	0.92	0.55–1.02
24 h-urine protein [mg/time]	711	74	50–80

Table 1. Initial laboratory findings and after 4 weeks of treatme	Table 1. Initia	laboratory	findings	and after 4	weeks of treatmer
---	-----------------	------------	----------	-------------	-------------------




Figure 1. Urticarial skin lesions on the right leg (A) and the left leg (B); computed tomography revealing hepatosplenomegaly (C)

Hodgkin's and non-Hodgkin's lymphomas has been reported, yet the mechanism behind this association is not fully established, as to whether hypocomplementemic urticarial vasculitis is the cause or the consequence of the malignancy [3].

It is important to be able to differentiate skin lesions related to urticarial vasculitis from those arising from chronic urticaria, as the former last more than 24 h, are sometimes described as painful or burning rather than pruritic and may cause residual hyperpigmentation of the skin [1, 4, 5], yet it should be taken into account that 5% to 10% of patients with CSU may present with urticarial vasculitis [2]. Also, it is crucial to acknowledge that CSU is more responsive to antihistamine therapy [4], whilst urtcarial vasculitis usually responds to corticosteroids, leading to remission of more than 80% of skin lesions [1, 6].

This report illustrates a rare case of hypocomplementemic urticarial vasculitis syndrome as part of a paraneoplastic manifestation following the diagnosis of chronic lymphocytic leukemia. Furthermore, it should be noted that skin lesions may develop even in patients with a prior history of chronic spontaneous urticaria. The presence of atypical lesions, lasting more than 24 h, associated with absence of clinical response to antihistamine therapy should arise one's clinical suspicion towards this pathology. Skin biopsy is essential for an accurate diagnosis.

Conflict of interest

The authors declare no conflict of interest.

References

- 1. Vallianou K, Skalioti C, Liapis G, et al. A case report of hypocomplementemic urticarial vasculitis presenting with membranoproliferative glomerulonephritis. BMC Nephrol 2020; 21: 351.
- 2. Buck A, Christensen J, McCarty M. Hypocomplementemic urticarial vasculitis syndrome: a case report and literature review. J Clin Aesthet Dermatol 2012; 5: 36-46.
- 3. William DJ. Cutaneous vascular diseases. In: Andrews' Diseases of the Skin. Elsevier 2020.
- 4. Wilson D, McCluggage WG, Wright GD. Urticarial vasculitis: a paraneoplastic presentation of B-cell non-Hodgkin's lymphoma. Rheumatology 2002; 41: 476-7.
- 5. Yuste-Chaves M, Unamuno-Pérez P. Cutaneous alerts in systemic malignancy: part I. Actas Dermosifiliogr 2013; 104: 285-98.
- 6. Loricera J, Calvo-Río V, Ortiz-Sanjuán F, et al. The spectrum of paraneoplastic cutaneous vasculitis in a defined population: incidence and clinical features. Medicine 2013; 92: 331-43.